Literature DB >> 8600316

Integrin-mediated interactions between primary/T-sv40 immortalized human glomerular epithelial cells and type IV collagen.

U Krishnamurti1, Y Chen, A Michael, Y Kim, W W Fan, J Wieslander, C Brunmark, E Rondeau, J D Sraer, F Delarue, E C Tsilibary.   

Abstract

The use of human glomerular epithelial cells (HGEC) in research has been severely restricted by several obstacles, which have been circumvented by the generation of T-SV40 immortalized human visceral glomerular epithelial cells (Delarue et al, 1991). In this work, we compared the primary and immortalized HGEC for expression of integrin and some nonintegrin surface receptors. We also studied the adhesion of both types of HGEC to glomerular basement membrane (GBM), type IV collagen (tIV), and its major noncollagenous NC1 domain. The integrins mediating adhesion of HGEC to tIV were also examined. Expression of integrin and some nonintegrin cell surface receptors was analyzed by flow cytometry. Adhesion to GBM, tIV, and its major noncollagenous NC1 domain was studied by direct solid phase cell adhesion assays. Identification of integrins mediating adhesion of HGEC to tIV was achieved by inhibition of cell adhesion using monoclonal antibodies to integrin subunits. The primary and immortalized HGEC share phenotypic characteristics, and alpha3beta1 appeared to be the major integrin present on both HGEC types. The kinetics of binding to GBM, tIV, and its noncollagenous NCI domain were similar in both the primary and immortalized HGEC, although the latter displayed a somewhat weaker binding. Both the primary and immortalized HGEC displayed significantly better adhesion to NC1-alpha3 compared with NC1-alpha1, alpha3beta1 appears to be the major integrin mediating the adhesion of HGEC to tIV. Our studies suggest that alpha3beta1 is the major integrin present on HGEC. This has been confirmed by flow cytometric analysis. In addition, we demonstrated a functional role for this integrin in mediating attachment of HGEC to tIV. Our data also demonstrate a preference in binding of HGEC to alpha3 chains of NC1 compared with alpha1 chains of NC1. These findings were seen in both the primary and immortalized HGEC. The T-SV40 immortalized HGEC can therefore serve as a very useful tool to study glomerular visceral cell biology.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8600316

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  5 in total

1.  Loss of type IV collagen alpha 5 and alpha 6 chains in human invasive prostate carcinomas.

Authors:  P Dehan; D Waltregny; A Beschin; A Noel; V Castronovo; K Tryggvason; J De Leval; J M Foidart
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

2.  Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor.

Authors:  Kim M Holwerda; Suzanne D Burke; Marijke M Faas; Zsuzsanna Zsengeller; Isaac E Stillman; Peter M Kang; Harry van Goor; Amy McCurley; Iris Z Jaffe; S Ananth Karumanchi; A Titia Lely
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

3.  Human podocytes adhere to the KRGDS motif of the alpha3alpha4alpha5 collagen IV network.

Authors:  Corina M Borza; Dorin-Bogdan Borza; Vadim Pedchenko; Moin A Saleem; Peter W Mathieson; Yoshikazu Sado; Heather M Hudson; Ambra Pozzi; Juan Saus; Dale R Abrahamson; Roy Zent; Billy G Hudson
Journal:  J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 10.121

4.  A different perspective on the filtration barrier after kidney stone formation: An immunohistochemical and biochemical study.

Authors:  Derya Karabulut; Emin Kaymak; Betül Yalçin; Harun Ulger; Didem Barlak Keti
Journal:  Urolithiasis       Date:  2020-11-05       Impact factor: 3.436

Review 5.  Biochemical composition of the glomerular extracellular matrix in patients with diabetic kidney disease.

Authors:  María M Adeva-Andany; Natalia Carneiro-Freire
Journal:  World J Diabetes       Date:  2022-07-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.